Advancing cell-based cancer immunotherapy through stem cell engineering.
Publication Year:
2023
PubMed ID:
36948187
Funding Grants:
- Stem Cell-Based iNKT Cell Therapy for Cancer
- HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma
- Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer
- Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells
- Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells
Public Summary:
Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the treatment of hematological malignancies. Although an important step forward for the field, autologous CAR-T therapies are hindered by high costs, manufacturing challenges, and limited efficacy against solid tumors. With ongoing progress in gene editing and culture techniques, engineered stem cells and their application in cell therapy are poised to address some of these challenges. Here, we review stem cell-based immunotherapy approaches, stem cell sources, gene engineering and manufacturing strategies, therapeutic platforms, and clinical trials, as well as challenges and future directions for the field.
Scientific Abstract:
Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the treatment of hematological malignancies. Although an important step forward for the field, autologous CAR-T therapies are hindered by high costs, manufacturing challenges, and limited efficacy against solid tumors. With ongoing progress in gene editing and culture techniques, engineered stem cells and their application in cell therapy are poised to address some of these challenges. Here, we review stem cell-based immunotherapy approaches, stem cell sources, gene engineering and manufacturing strategies, therapeutic platforms, and clinical trials, as well as challenges and future directions for the field.